THE OFFICIAL NEWS SOURCE OF ACR CONVERGENCE 2022 • NOVEMBER 10-14
-
Expanding treatment options means comorbidities matter when selecting RA treatment
Faculty in How I Treat Difficult RA: Panel Session reviewed difficult-to-treat cases for RA patients with ILD, refractory RA, and RA with liver disease. READ MORE
-
Panel discusses evolution, future considerations of SLE damage assessment index
Quantifying the severity of SLE damage remains a challenge, and an ACR Convergence 2020 session discussed issues pertaining to the development of an improved strategy. READ MORE
-
Rheumatologists can lead their patients to reliable information in the digital world
As more and more patients with rheumatic diseases turn to the digital world for information and support, rheumatologists and their care teams need to know how to guide their patients toward reputable information and away from potentially harmful outcomes. READ MORE
-
CCP arthritis remains under the radar, but research could lead to treatment breakthroughs
Calcium pyrophosphate (CCP) arthritis was first described more than 50 years ago. Since then, researchers have found that this extremely painful type of arthritis is extraordinarily common but significantly underdiagnosed. READ MORE
-
Session will examine how modulating the microbiome can affect rheumatoid arthritis
The microbiome presents a tremendous opportunity for understanding disease because it’s able to be manipulated once you find the right way, but there’s still so much unknown about finding the right way to manipulate the microbiome. READ MORE
-
FDA leaders will address challenges and opportunities in pediatric study designs
The FDA is employing extrapolation of adult efficacy data in drug development programs in rheumatology conditions that demonstrate a similar disease pathophysiology and clinical presentation, similar co-morbidities, and similar response to therapy in pediatric rheumatology patients to achieve the goal of shortening timelines for pediatric drug development, READ MORE
-
Studies look at whether preclinical treatment may delay, prevent RA
Research continues into finding ways to treat rheumatoid arthritis early enough to delay the onset of symptoms or possibly reverse the course of the disease entirely and keep arthritis from developing. READ MORE
-
New molecular targets could advance OA treatment
Only in the past 15 years or so have people accepted the idea that molecular targeting could lead to disease modification in osteoarthritis, and an ACR Convergence 2020 educational session will cover the latest targets in preclinical models and early phase trials involving both mice and humans. READ MORE
-
Mothers with rheumatic diseases need more support from healthcare providers
The education session Reproductive Health: Meet Women’s Needs features three speakers who not only work with patients with rheumatic disease but are also mothers who live with a rheumatic disease. READ MORE
-
Kristina Clark, MD, MRCP: Blister fluid and plasma in systemic sclerosis
MEET THE POSTER PRESENTER: SSc is a severe rheumatic disease with high mortality from lung and heart disease, and major non-lethal clinical burden, including fibrosis of the skin. Sampling skin gives a unique opportunity to explore local disease mechanisms and better understand pathogenesis. READ MORE